Kyverna Therapeutics, Inc.
Key Metrics
Market Snapshot
About
Kyverna Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing cell therapies for autoimmune diseases. The company's lead product candidate utilizes chimeric antigen receptor (CAR) T-cell technology to selectively deplete B cells that drive autoimmune conditions. Kyverna's pipeline targets diseases such as lupus nephritis, myasthenia gravis, and multiple sclerosis, applying oncology-derived cell therapy approaches to autoimmune disorders.